Entrada Therapeutics Grants Stock Options and RSUs to New Employees Under 2025 Inducement Plan
Entrada Therapeutics Inc. has granted a total of 40,650 restricted stock units (RSUs) and options to purchase 38,850 shares of its common stock to five newly-hired non-executive employees under the 2025 Inducement Equity Plan. The stock options have an exercise price of $9.91 per share, matching the closing price on December 1, 2025. For each employee, one-fourth of the stock options will vest on the one-year anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the next three years. Similarly, one-fourth of the RSUs will vest after one year, with 6.25% vesting quarterly thereafter. Vesting is contingent on continued employment or service with the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596222-en) on December 04, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。